The U.S. Department of Labor’s Employee Benefits Security Administration (EBSA) issued a landmark final rule on Thursday designed to dismantle the opaque pricing structures used by pharmacy benefit managers (PBMs). The regulation, which targets the "middlemen" of the healthcare industry, requires unprecedented levels of transparency regarding fees, compensation, and drug manufacturer rebates. By forcing these entities to pull back the curtain on their financial arrangements, federal officials and advocacy groups expect to significantly reduce the cost of healthcare for millions of American workers and their employers.
Under the new federal mandate, PBMs and their various affiliates are legally required to disclose comprehensive details of their compensation to self-insured employers. These disclosures must include all rebates received from drug manufacturers, as well as any payments recouped from pharmacies through "clawback" mechanisms. Furthermore, the rule takes a direct aim at the controversial practice of spread pricing. This occurs when a PBM charges a health plan a higher price for a prescription drug than the amount it actually reimburses the pharmacy, pocketing the difference as profit. The final rule now requires PBMs to explicitly disclose the compensation received through these spread pricing arrangements.
The Department of Labor (DOL) has projected that this increased transparency and the subsequent ability for employers to negotiate more favorable terms will lower prescription drug costs for health plans by approximately $22 billion over the next decade. Beyond mere disclosure, the rule empowers employers with the legal right to audit these financial records and provides a mechanism for relief if a PBM fails to fulfill its fiduciary or contractual responsibilities.
The Evolution of the PBM Industry and the Need for Reform
To understand the significance of the DOL’s final rule, one must examine the evolution of pharmacy benefit managers within the American healthcare ecosystem. Originally established in the 1960s to process claims and develop formularies, PBMs have grown into massive, vertically integrated entities that exert immense influence over which drugs patients can access and at what price. Today, the three largest PBMs—CVS Caremark, Express Scripts, and OptumRx—control approximately 80% of the market, often operating under the same corporate umbrellas as major health insurers and retail pharmacies.
For decades, PBMs have operated within what many critics describe as a "black box." Because they sit between drug manufacturers, insurers, and pharmacies, they have been able to negotiate secret rebates from pharmaceutical companies in exchange for placing certain drugs on "preferred" lists, or formularies. While PBMs argue that these rebates help lower overall costs, transparency advocates point out that the list prices of drugs often rise to accommodate these rebates, and the savings are not always passed down to the employers or the patients at the pharmacy counter.
The lack of transparency has been particularly problematic for self-insured employers. Under the Employee Retirement Income Security Act (ERISA), these employers have a fiduciary duty to manage their health plans in the best interest of their employees. However, without access to the specific financial data regarding rebates and spread pricing, many plan sponsors have found it impossible to determine if they are receiving a fair deal or if their PBM is siphoning off excessive profits.
Chronology of Legislative and Regulatory Action
The final rule announced this week is the culmination of years of mounting pressure from both sides of the political aisle to address rising drug costs. The timeline of this specific regulatory shift began in earnest with the passage of the Consolidated Appropriations Act of 2026 (CAA 2026).
Earlier this year, Congress passed the CAA 2026, which laid the groundwork for significant PBM reform. Key provisions of that legislation included the "delinking" of PBM compensation from the list price of drugs within the Medicare Part D program—a move intended to remove the incentive for PBMs to favor high-priced drugs that yield larger rebates. The CAA 2026 also mandated more detailed reporting from PBMs to plan sponsors, but many advocates argued that the legislation left loopholes that allowed PBMs to continue hiding certain types of "indirect" compensation.
In response to these gaps, the Department of Labor’s EBSA began drafting the final rule to ensure that the spirit of the CAA 2026 was applied to the private sector, specifically to ERISA-governed self-insured plans. Throughout the middle of 2026, the DOL engaged in a public comment period, receiving thousands of submissions from patient advocacy groups, employer coalitions, and the PBM industry itself. The final rule issued this Thursday represents the department’s definitive stance on the matter, effectively closing the "transparency gap" that remained after the initial legislation.
Detailed Provisions: Audits, Disclosures, and Spread Pricing
The final rule introduces several technical requirements that fundamentally alter the PBM-employer relationship. The most significant of these is the mandatory disclosure of "indirect compensation."
- Spread Pricing Transparency: PBMs must now disclose the exact dollar amount of the "spread" on every transaction where the price charged to the plan exceeds the price paid to the pharmacy. This practice has long been a primary revenue driver for PBMs, particularly in the generic drug market.
- Rebate Pass-Through Tracking: The rule requires PBMs to provide an itemized account of all rebates, discounts, and "price protection" payments received from drug manufacturers. Employers will now be able to see exactly how much of a manufacturer’s rebate is being kept by the PBM as an administrative fee and how much is being credited back to the health plan.
- Audit Rights and Accountability: Perhaps the most impactful change is the formalization of audit rights. Under the new rule, if a PBM refuses to provide the required data or if the data provided is found to be inaccurate, the employer (plan sponsor) has a clear path to seek relief. This includes the potential to terminate contracts without penalty and seek reimbursement for undisclosed fees.
- Fiduciary Alignment: By requiring these disclosures, the DOL is aligning PBM practices with the fiduciary requirements of ERISA. Plan sponsors are now legally empowered—and arguably legally obligated—to use this newly available data to ensure they are not overpaying for pharmacy benefits.
Reactions from Industry Stakeholders and Advocacy Groups
The announcement of the final rule was met with a mixture of celebration and sharp criticism, reflecting the deep divisions within the healthcare sector.
Secretary of Labor Keith Sonderling framed the rule as a victory for the American worker. "This is a win for every American worker who has ever paid too much at the pharmacy counter," Sonderling said in an official statement. "For years, PBMs have operated in the shadows, pocketing hidden fees while workers and employers were left in the dark. This rule brings that era of secrecy to an end."
The ERISA Industry Committee (ERIC), which represents the interests of large employers who provide health benefits to millions of workers, hailed the move as a long-overdue correction. James Gelfand, president and CEO of ERIC, noted that the rule finally gives employers the tools they need to manage their costs. "Large employers pay for their workers’ prescriptions, but many can’t see how much of that money their PBM and any affiliated entity keeps," Gelfand said. "This rule changes that. Employers will be able to check the numbers, ask hard questions, and hold their vendors accountable to the contract."
Similarly, the National Community Pharmacists Association (NCPA) applauded the DOL’s decision. Community pharmacists have long complained that PBM "clawbacks" and low reimbursement rates—combined with high spread pricing—have forced many independent pharmacies out of business. Ronna Hauser, NCPA’s senior vice president of policy and pharmacy affairs, stated that the rule creates "additional transparency for the first time," allowing for a more equitable playing field between local pharmacies and massive PBM entities.
Conversely, the Pharmaceutical Care Management Association (PCMA), the national trade association representing PBMs, expressed significant concerns. David Marin, president and CEO of the PCMA, argued that the rule could inadvertently hurt the very people it aims to help. "The Department may have exceeded Congress’s intent and its own authority," Marin said. He suggested that the "excessive reporting demands" could lead to further industry consolidation, as smaller PBMs may lack the administrative infrastructure to comply with the rigorous disclosure requirements. Marin also warned that the rule might make prescription drug benefits more expensive by disrupting the confidential negotiations that PBMs use to secure discounts.
Analysis of Economic and Industry Implications
The DOL’s projection of $22 billion in savings over 10 years is rooted in the belief that transparency will trigger a competitive shift in the market. When employers can see the "spread" and the "rebates," they are likely to move toward "pass-through" models, where the PBM charges a flat administrative fee per member or per claim, rather than profiting off the volatility of drug prices.
However, the implications go beyond mere cost-cutting. This rule may fundamentally change the business models of the "Big Three" PBMs. If spread pricing and retained rebates are curtailed, these companies may seek to recoup lost revenue through higher transparent administrative fees or by further pushing patients toward their own specialty and mail-order pharmacies.
There is also the matter of legal liability for employers. In recent years, several high-profile class-action lawsuits have been filed by employees against their employers (such as the 2024 suit against Johnson & Johnson), alleging that the companies breached their fiduciary duty by failing to oversee PBM contracts and allowing the plan to pay inflated prices for generic drugs. The DOL’s final rule effectively removes the "we didn’t have the data" defense for employers. Moving forward, plan sponsors who do not actively audit their PBMs and negotiate based on the newly disclosed data could face increased litigation risk from their own employees.
Furthermore, the rule may influence the broader debate on drug pricing in the United States. By exposing the gap between what a manufacturer charges and what a patient pays, the rule provides policymakers with concrete data to determine whether the high cost of medicine is driven by pharmaceutical innovation or by middleman markups.
Future Outlook and Implementation
The implementation of the final rule is expected to begin in the coming fiscal year, though PBM industry groups may pursue litigation to delay or overturn parts of the regulation, citing regulatory overreach. If the rule stands, the next two to three years will likely see a massive wave of contract renegotiations across the private sector as employers utilize their new audit rights.
While the $22 billion in projected savings represents a significant sum, it is a fraction of the nearly $500 billion spent annually on prescription drugs in the U.S. Nonetheless, many health policy experts view this as a foundational step. By addressing the "shadow" compensation of PBMs, the Department of Labor has set a precedent for transparency that could eventually extend to other opaque areas of healthcare, such as hospital billing and insurance brokerage commissions.
For the average American worker, the impact of this rule may not be felt immediately at the pharmacy counter, but the long-term goal is clear: by lowering the costs for the "plan," the rule aims to stabilize premiums and reduce the out-of-pocket burden on families who have struggled with the rising cost of essential medications. As the healthcare industry adjusts to this new regulatory environment, the focus will remain on whether transparency alone is enough to break the cycle of escalating drug prices or if further direct price interventions will be necessary.
